RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — 28th Annual ROTH Conference 2016

35 slides from RespireRx Pharmaceuticals's conference presentation, Mar 11, 2016

  1. Slide 1: RespireRx Pharmaceuticals - 28th Annual ROTH Conference

    RespireRx Pharmaceuticals Inc OTC QB: RSPI James S. Manuso, Ph.D., President & CEO 28™ ANNUAL ROTH CONFERENCE MARCH 15, 2016, LA‘ |A NIGUEL, CA Medicines for Respiratory Diseases

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements GQ) RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," “e

  3. Slide 3: Breath

    Breath GQ) RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life.” beeees Abbot George Burke

  4. Slide 4: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 or Phase 2-ready development programs o Three pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent

  5. Slide 5: Company Focus

    ° ° ° ° ° Company Focus WN Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) Drug-induced Respiratory Depression (RD) - Ampakines = Acute use — surgical anesthesia/sedation = Semi-acute use — post-surgical pain management with opioids = Chronic use

  6. Slide 6: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline (A)Resp pireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea Central Sleep Apnea —— ap CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CX717 with Opioids for Reduced Repertory Depressi

  7. Slide 7: Sleep Apnea

    Sleep Apnea A) RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed o The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep apneas =

  8. Slide 8: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) A) RespireRx Pharmaceuticals Inc o Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep = Induced by relaxation of muscles during sleep = Soft tissue in back of throat collapses and obstructs upper airway o Significant morbidity due to stro

  9. Slide 9: CPAP Efficacy is Severely Limited

    CPAP Efficacy is Severely Li Patient Compliance Standard of Care Works as an air splint to keep upper airway open during sleep 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year Many CPAP users wear the device for

  10. Slide 10: Dronabinol: Breakthrough Treatment for OSA

    Dronabinol: Breakthrough Treatment for OSA Resp pireRx Pharmaceuticals Inc o Mechanism of Action = Dronabinol is (delta 9) THC, a cannabinoid agonist o Background = Schedule Ill drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients and

  11. Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Completed Phase 2A Trial of Dronabinol in OSA Ad RespireRx Pharmaceuticals Inc o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days « 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polyso

  12. Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    ronabinol Proven to Reduce Apnea in OSA Subjects Reduction in Sleep Apnea 40% P=0.17 Dronabinol Placebo P<0.01 RespireRx Pharmaceuticals Inc 12

  13. Slide 13: Apnea Suppression as a Function of Dose and Time

    Apnea Suppression as a Function of Dose and Time RespireRx Pharmaceuticals Inc 1st Half 2nd Half AAHI versus Baseline 86 R&B Bw we n=17 n= 13, n=8 The plasma half-life of dronabinol is 2 — 4 hours. 13

  14. Slide 14: Ongoing Dronabinol Phase 2B Clinical Trial in OSA

    Ongoing Dronabinol Phase 2B Clinical Trial in OSA (A) Resp ireRx o Sponsored and led by U of Illinois o 4 major centers, fully funded by NIH o Potentially pivotal for an NDA submission o Doses: Placebo, 2.5 mg, 10 mg qd o 120 subjects (40/group, 6 weeks dosing) o Data expected Q3/2016 o Meet with FD

  15. Slide 15: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market A) RespireRx o Licensed issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics and medical marijuana a

  16. Slide 16: The Dronabinol Opportunity

    The Dronabinol Opportunity A) RespireRx Pharmaceuticals Inc Impact on Pa Commercial Opportunity First medicine available for OSA Changes the nature of OSA treatment Ease of Use/Better Patient Compliance Broadly expands prescriber base from sleep specialists to include primary care physicians and car

  17. Slide 17: Central Sleep Apnea

    Central Sleep Apnea Resp pireRx Pharmaceuticals Inc o Caused by a lack of drive from the brain to breathe during sleep o Manifestations of CSA = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No medicine or device is approved for the

  18. Slide 18: Severity of CSA is Correlated with Increased Mortality

    Severity of CSA is Correlated with Increased Mortality in P Heart Failure Patients RespireRx 0) 9) 2 ‘6 AHI less than 5 per hour ul ‘ooo AHI equal or greater than 5 per hour ra) Reducing Central : | Sleep Apnea May @ Reduce Mortality in a Heart Failure Patients eal 4 0D DO 1H M 1 O MH MH WH W W HO B

  19. Slide 19: AMPAKINES - A Novel Class of Medicines

    AMPAKINES -— A Novel Class of Medicines A) Resp pireRx Pharmaceuticals Inc AMPA Receptors Mediate Synaptic Transmission in the Brain AMPAKINE o Glutamate is the major excitatory neurotransmitter in the CNS o Fast excitatory transmission is mediated by AMPA-type glutamate receptors o Ampakines are po

  20. Slide 20: AMPAKINES - Novel Treatments for Respiratory Depression

    AMPAKINES — Novel Treatments for Respiratory Depression (A) RespireRx Pharmaceuticals Inc ‘<) esophagus PreBétzinger PreBétzinger Complex Complex o Neurons in this brainstem region control inspiratory breathing rhythm o PreBotC neurons use AMPA receptors for signaling o Opioids and other depressants

  21. Slide 21: CX1739: A Third Generation, Oral Ampakine

    CX1739: A Third Generation, Oral Ampakine in Phase 2 RespireRx Pharmaceuticals Inc o Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression = Combination formulation with an opioid for treatment of chronic pain o Stage of Development = Suc

  22. Slide 22: CX1739: Completed Phase 2A in Sleep Apnea

    CX1739: Completed Phase 2A in Sleep Apnea WN RespireRx seceded foc Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a single dose of 90

  23. Slide 23: Patient Selection: CX1739 Was More Effective in Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas GQ Resp pireRx Pharmaceuticals Inc Obstructive Apneas Mixed Apneas Central Apnea 3 6 12 30 5 10 piers ic Rc SE oe4 SE 8 £ G 20. £G £3 ot w £3 we 6 2 3% 2¢ 23 Si 6. 2 au 4. ze 0 au Ea ; : CJ ; 0 0 0 = rs) yo Yo SS

  24. Slide 24: Drug-induced Respiratory Depression

    ° ° ° Drug-induced Respiratory Depression Resp pireRx Pharmaceuticals Inc RD is the most frequent lethal side effect of opioid use Acute and Semi-Acute Use of opioids « ~25M patients/year at risk for Respiratory Depression (hospitalized, peri- and post-surgical opioid patients) Chronic Opioid Use «

  25. Slide 25: Ampakines Prevent Opioid-induced Respiratory Depression

    Ampakines Prevent Opioid-induced Respiratory Depression Resp pireRx Pharmaceuticals Inc o Two clinical studies in normal, healthy volunteers with CX717, a second-generation Ampakine o Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil o Respiratory and a

  26. Slide 26: CX717 Prevents Opioid-induced Respiratory Depression in Humans

    CX717 Prevents Opioid-induced Respiratory Depression in Humans GQ Resp pireRx Pharmaceuticals Inc 16 NS —_—_ (Placebo —™. waecx717 ge 12 £ a *P<0.01 = 8 NS - Not Significant oO 2 a 4 Data are expressed as the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. 0. Baseline +Alfentan

  27. Slide 27: CX717 Does Not Interfere With the Analgesic Properties of Opioids

    CX717 Does Not Interfere With the Analgesic Properties of Opioids BW RespireRx che ot ied Inc Analgesia 2.0 [Placebo 215 waacx717 2 2 o 5 1.0 NS. 2) c cc a 0.5: Delivery of a electrical stimulation to finger ’ ’ 0.0: Alfentanil reduced the pain sensitivity Baseline +Alfentanil +Naloxone (produced an

  28. Slide 28: CX1739: Phase 2A in Opioid-Induced Respiratory Depression

    CX1739: Phase 2A in Opioid-Induced Respiratory Depression GQ Rese pireRx Pharmaceuticals Inc Protocol Antagonism of Opioid-Induced Respiratory Depression by CX1739 with Preservation of Opioid Analgesia Design Randomized, Blinded, Placebo-controlled, Cross-Over with Dose Escalation Dosing Each subjec

  29. Slide 29: Key Objectives (Pending Financing)

    Key Objectives for 20 (Pending Financing) GQ Resp pireRx Pharmaceuticals Inc Compound Indication Status Estimated Estimated Start Date Completion Dronabinol Obstructive Sleep Apnea Phase 2B Underway 3Q2016 CX1739 Opioid-induced RD Phase 2A 1Q2016 2Q2016 Central Sleep Apnea Phase 2A 3Q2016 2Q2017 CX1

  30. Slide 30: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline (A)Resp pireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea Central Sleep Apnea —— ap CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CX717 with Opioids for Reduced Repertory Depressi

  31. Slide 31: NIH-Supported Programs in Drug Abuse

    NIH-Supported Programs in Drug Abuse A) RespireRx o Non-Core Programs in Drug Abuse and Addiction = Cocaine and Amphetamines = Research and development program with NIDA = NIDA contracts with specialist labs and pays for animal studies = Company provides compounds and retains all rights 31

  32. Slide 32: Capital Structure & Market Metrics

    Capital Structure (t & Market Metrics usands of shares) Total as of September 30, 2015 Common Stock 477,221 Common Stock Equivalents of all Convertibles (Preferred Stock and Convertible Notes) 95,934 Common Stock Equivalents of all Options and 380,247 Warrants Total 953,402 March 8, 2016 Closing pri

  33. Slide 33: Management and Directors

    Management and Directors A James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director CCO Agile Therapeutics Director CEO

  34. Slide 34: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 or Phase 2-ready development programs o Three pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent

  35. Slide 35: RespireRx Pharmaceuticals - 28th Annual ROTH Conference

    RespireRx Pharmaceuticals Inc OTC QB: RSPI James S. Manuso, Ph.D., President & CEO 28™ ANNUAL ROTH CONFERENCE MARCH 15, 2016, LA‘ |A NIGUEL, CA Medicines for Respiratory Diseases 35

RespireRx Pharmaceuticals — 28th Annual ROTH Conference 2016 on 6ix